$0.29
-0.01 (-3.29%)
Open$0.29
Previous Close$0.30
Day High$0.30
Day Low$0.27
52W High$1.12
52W Low$0.35
Volume—
Avg Volume1.18M
Market Cap29.52M
P/E Ratio—
EPS$-0.80
SectorBiotechnology
Analyst Ratings
Buy
15 analysts
Price Target
+4,005.6% upside
Current
$0.29
$0.29
Target
$11.82
$11.82
$9.31
$11.82 avg
$19.97
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 193.6K | 734.7K | 11.28M |
| Net Income | -77,160,103 | -263,544,943 | 2.04M |
| Profit Margin | -39,009.5% | -37,059.0% | 18.1% |
| EBITDA | -80,122,214 | -288,865,667 | 2.88M |
| Free Cash Flow | — | — | 1.40M |
| Rev Growth | -73.7% | -73.7% | +22.8% |
| Debt/Equity | 0.01 | 0.01 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |